Lancet·Oct 27LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialRandomized trial in 72 peopleGLP-1 receptor agonistsPaper
Cell Metabolism·Aug 18LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptTrial in peopleInterventionsPaper